Peter Borchmann, MD | Authors


Safety Data From the Phase II JULIET Trial in DLBCL

November 28, 2018

Peter Borchmann, MD, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma.